BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27370408)

  • 1. Abnormalities in biomarkers of mineral and bone metabolism in kidney donors.
    Kasiske BL; Kumar R; Kimmel PL; Pesavento TE; Kalil RS; Kraus ES; Rabb H; Posselt AM; Anderson-Haag TL; Steffes MW; Israni AK; Snyder JJ; Singh RJ; Weir MR
    Kidney Int; 2016 Oct; 90(4):861-8. PubMed ID: 27370408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low serum levels of intact osteocalcin in patients with congestive heart failure.
    Schleithoff SS; Zittermann A; Stüttgen B; Tenderich G; Berthold HK; Körfer R; Stehle P
    J Bone Miner Metab; 2003; 21(4):247-52. PubMed ID: 12811631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.
    Pietrzyk B; Wyskida K; Ficek J; Kolonko A; Ficek R; Więcek A; Olszanecka-Glinianowicz M; Chudek J
    Int Urol Nephrol; 2019 Mar; 51(3):519-526. PubMed ID: 30584645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
    Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G
    Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency.
    Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; Di Nero G
    J Pediatr; 1993 Jan; 122(1):37-45. PubMed ID: 8419613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional study on biochemical parameters of bone turnover and vitamin d metabolites in healthy dutch children and young adults.
    van der Sluis IM; Hop WC; van Leeuwen JP; Pols HA; de Muinck Keizer-Schrama SM
    Horm Res; 2002; 57(5-6):170-9. PubMed ID: 12053089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in bone mass and serum markers of bone metabolism after parathyroidectomy.
    Thorsen K; Kristoffersson AO; Lorentzon RP
    Surgery; 1997 Nov; 122(5):882-7. PubMed ID: 9369887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.
    Young A; Hodsman AB; Boudville N; Geddes C; Gill J; Goltzman D; Jassal SV; Klarenbach S; Knoll G; Muirhead N; Prasad GV; Treleaven D; Garg AX;
    Am J Kidney Dis; 2012 Jun; 59(6):761-9. PubMed ID: 22093959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone metabolism dynamics in the early post-transplant period following kidney and liver transplantation.
    Schreiber PW; Bischoff-Ferrari HA; Boggian K; Bonani M; van Delden C; Enriquez N; Fehr T; Garzoni C; Hirsch HH; Hirzel C; Manuel O; Meylan P; Saleh L; Weisser M; Mueller NJ;
    PLoS One; 2018; 13(1):e0191167. PubMed ID: 29338022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adaptation and relationship of FGF-23 to changes in mineral metabolism in Graves' disease.
    Park SE; Cho MA; Kim SH; Rhee Y; Kang ES; Ahn CW; Cha BS; Lee EJ; Kim KR; Lee HC; Lim SK
    Clin Endocrinol (Oxf); 2007 Jun; 66(6):854-8. PubMed ID: 17437520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men.
    Gram J; Junker P; Nielsen HK; Bollerslev J
    Bone; 1998 Sep; 23(3):297-302. PubMed ID: 9737353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
    Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
    Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations of new markers of bone formation and resorption in kidney transplant recipients.
    Małyszko J; Wołczyński S; Małyszko JS; Konstantynowicz J; Kaczmarski M; Myśliwiec M
    Transplant Proc; 2003 Jun; 35(4):1351-4. PubMed ID: 12826157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D status and markers of bone turnover in Caucasian and South Asian postmenopausal women living in the UK.
    Lowe NM; Mitra SR; Foster PC; Bhojani I; McCann JF
    Br J Nutr; 2010 Jun; 103(12):1706-10. PubMed ID: 20102676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered bone and mineral metabolism in patients receiving imatinib mesylate.
    Berman E; Nicolaides M; Maki RG; Fleisher M; Chanel S; Scheu K; Wilson BA; Heller G; Sauter NP
    N Engl J Med; 2006 May; 354(19):2006-13. PubMed ID: 16687713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure.
    Tsuchida T; Ishimura E; Miki T; Matsumoto N; Naka H; Jono S; Inaba M; Nishizawa Y
    Osteoporos Int; 2005 Feb; 16(2):172-9. PubMed ID: 15164161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease.
    Valdemarsson S; Lindergård B; Tibblin S; Bergenfelz A
    J Intern Med; 1998 Feb; 243(2):115-22. PubMed ID: 9566639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.